BioCentury

7:00 AM GMT, May 28, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/25 cls
Affymax Inc. (NASDAQ:AFFY) MLV Ed Arce Price target Buy 8% $14.07
Arce raised his target to $21 from $12 after Affymax and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) launched once-monthly Omontys peginesatide in the U.S. to treat anemia in chronic kidney disease (CKD) patients who are on dialysis (see BioCentury, April 30). He believes the net overall cost of Omontys will be lower than anemia drug Epogen epoetin

Read the full 955 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.